Clinical Trial Update: A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating the effect of severe hepatic impairment on the pharmacokinetics of intravenous conivaptan; the study has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Vaprisol (Conivaptan)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Liver Disease | Phase 1 | Status: COMPLETED